PGY Pagaya Technologies Valuation — May 2026

by psind707

Date: May 18, 2026
Spot Price: $12.87
Framework: Kong/Damodaran — three-scenario probability-weighted DCF + peer relative cross-check + SBC discipline

Current State (verified)

Q1 2026 Actuals

• Revenue: $318M (+10% YoY)
• Network Volume: $2.6B (+9% YoY, +23% ex-SFR)
• FRLPC: $121M (+5% YoY) at 4.6% of volume (down 19bps YoY)
• Adj EBITDA: $94M (+18% YoY, 29.6% margin)
• GAAP Net Income: $25M (+218% YoY)
• OCF: $43M
• Diluted EPS: $0.28

FY26 Guidance (raised on May 7)

• Revenue: $1.40–1.575B
• Adj EBITDA: $420–460M
• GAAP NI: $110–160M
• FRLPC% of volume: 4–5%

SBC Discipline — Owner Economics

Reported Adj EBITDA of $440M (FY26 mid) does not convert cleanly to owner FCF. ABS risk retention reinvestment ties up capital even though it's recycled. SBC is real cash expense per Kong framework.

Multiple Reality Check

The headline multiple flatters the picture. True owner FCF is what matters.

Peer Comp Table (May 18, 2026)

PGY is the cheapest in the cohort by EV/EBITDA at 4.0x. UPST and LC trade at 2x PGY's EBITDA multiple despite slower 2026 growth.

The discount reflects:

1. Israel geopolitical risk
2. ABS funding model concerns
3. Dilution overhang (96.7M diluted vs 82.5M basic = 17%)
4. Impairment volatility ($36M Q1 hit on retained securities)

Reverse DCF — What's Priced In

EV of $1.78B at peer-average 7x EV/EBITDA implies steady-state Adj EBITDA of just $255M — materially below the $440M midpoint guide.

Market is pricing in either:

• (a) 40%+ EBITDA degradation, or
• (b) Sustained 4x discount multiple

Either implies the bull case is not in the price.

Three-Scenario Probability-Weighted DCF

WACC Inputs

• Risk-free rate: 4.3% (10Y Treasury)
• Equity risk premium: 5.5%
• Beta: 1.5
• Israel country risk premium: 1.0%
• Cost of equity: 13.5%
• After-tax cost of debt: 6.5%
• Capital structure: 60% equity / 40% debt
• WACC: approximately 9.7%

By 2030, fully diluted shares estimated at 115M (5%/yr SBC drag).

Scenarios

Probability-weighted FV (discounted): approximately $13.40 per share

vs. $12.87 spot → approximately 4% upside / fairly valued, positively skewed

What Sets PGY Apart vs. UPST

A direct comparison with the prior UPST thesis is instructive given similar AI-underwriting positioning.

PGY is structurally better-funded than UPST today — and trades at half the EBITDA multiple. The ABS data that destroyed UPST's premium thesis (rising CE requirements, KBRA Feb 2026 subordinate downgrades) is trending the opposite way for PGY.

Risks

1. Israel geopolitical — operations split NY/Tel Aviv; military service obligations; explicit 10-K risk factor; Iran/Strait of Hormuz backdrop remains live
2. ABS market cyclicality — 2022 stress shut the market for weeks; PGY survived but credit retention took losses
3. Dilution treadmill — $60M annual SBC = approximately 5% annual dilution at current price; no buyback authorized
4. Impairment volatility — Q1 $36M impairment on retained securities; spike here is the earliest credit warning
5. CEO/CFO transition — Dobres (CSO) becomes CFO June 15, 2026; execution risk during handoff
6. Application conversion below 1% — tighter underwriting compressing top of funnel

Recommendation

HOLD / MODERATE BUY at $12.87.

PWFV approximately $13.40 suggests fairly valued with positive skew. The thesis works if:

• 4 consecutive profitable quarters becomes 8
• ABS market remains functional through 2026
• FRLPC% stabilizes at 4.5%+ (vs. 4.6% Q1; guidance 4–5%)

Market is pricing PGY as a UPST-like fragile model when the funding architecture and credit performance argue otherwise. Asymmetry is positively skewed (approximately $10 upside vs. approximately $10 downside) but execution-dependent.

Position Sizing

• Small initial position: 1–2%
• Add on dips to <$11
• Add on Q2 EBITDA print >$110M (vs. guide $100–115M midpoint)

Single-Leg Options Angle

• Underlying liquidity decent but options chains thin
• Jan 2027 $13 calls express bullish view with full year for guidance to play out
• Avoid short-dated — earnings just printed May 7; next catalyst is August Q2 print

Key Thesis-Break Conditions

• Q2 impairment line >$50M
• FRLPC% drops below 4.0%
• Any ABS shelf downgrade by KBRA/Fitch
• Application conversion deteriorates further (<0.8%)
• New geopolitical escalation forcing Tel Aviv ops disruption

Disclosure: This analysis is for informational purposes only and does not constitute investment advice. The author is not a registered investment advisor. Always conduct independent research and consult a licensed financial professional before making investment decisions.